Real-world characteristics and outcomes of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in Australia: the COALA project.

22 Among patients with BRAF V600E mutations, there is a trend for improvement in OS for EC-treated patients but this did not reach statistical significance likely due to the small sample size. 15 Fewer BRAF V600E patients accessed 3L therapies and the OS for those with a BRAF V600E -mutated tumour remained inferior to those with wild-type tumours.

also in 111,027 other papers